Global Multivalent Influenza Vaccines Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
The global market for Multivalent Influenza Vaccines is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Multivalent Influenza Vaccines market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Multivalent Influenza Vaccines market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Multivalent Influenza Vaccines market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Multivalent Influenza Vaccines market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Multivalent Influenza Vaccines players cover Sanofi, CSL, GSK, Viatris and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Multivalent Influenza Vaccines market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Multivalent Influenza Vaccines market, with both quantitative and qualitative data, to help readers understand how the Multivalent Influenza Vaccines market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Multivalent Influenza Vaccines market and forecasts the market size by Type (Trivalent Inactivated Influenza Vaccine (IIV3), Trivalent Live Attenuated Vaccine (LAIV3) and Quadrivalent Inactivated Influenza Vaccine (IIV4)), by Application (6 Months to 3 Years and Above 3 Years.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Chapter 1: Scope of Multivalent Influenza Vaccines, Research Methodology, etc.
Chapter 2: Executive Summary, global Multivalent Influenza Vaccines market size (sales and revenue) and CAGR, Multivalent Influenza Vaccines market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Multivalent Influenza Vaccines sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Multivalent Influenza Vaccines sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Multivalent Influenza Vaccines market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac and Bcht Biotechnology, etc.
Chapter 14: Research Findings and Conclusion
The global market for Multivalent Influenza Vaccines is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Multivalent Influenza Vaccines market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Multivalent Influenza Vaccines market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Multivalent Influenza Vaccines market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Multivalent Influenza Vaccines market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Multivalent Influenza Vaccines players cover Sanofi, CSL, GSK, Viatris and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Multivalent Influenza Vaccines market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Multivalent Influenza Vaccines market, with both quantitative and qualitative data, to help readers understand how the Multivalent Influenza Vaccines market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Multivalent Influenza Vaccines market and forecasts the market size by Type (Trivalent Inactivated Influenza Vaccine (IIV3), Trivalent Live Attenuated Vaccine (LAIV3) and Quadrivalent Inactivated Influenza Vaccine (IIV4)), by Application (6 Months to 3 Years and Above 3 Years.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
- Trivalent Inactivated Influenza Vaccine (IIV3)
- Trivalent Live Attenuated Vaccine (LAIV3)
- Quadrivalent Inactivated Influenza Vaccine (IIV4)
- 6 Months to 3 Years
- Above 3 Years
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- CSL
- GSK
- Viatris
- AstraZeneca
- Hualan Bio
- Changchun Institute of Biological
- Sinovac
- Bcht Biotechnology
- Jiangsu GDK
- KM Biologics
- ADIMMUNE Corporation
- Aleph Biomedical
- Shanghai Institute of Biological Products
- Zhongyianke Biotech
- Wuhan Institute of Biological Products
Chapter 1: Scope of Multivalent Influenza Vaccines, Research Methodology, etc.
Chapter 2: Executive Summary, global Multivalent Influenza Vaccines market size (sales and revenue) and CAGR, Multivalent Influenza Vaccines market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Multivalent Influenza Vaccines sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Multivalent Influenza Vaccines sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Multivalent Influenza Vaccines market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac and Bcht Biotechnology, etc.
Chapter 14: Research Findings and Conclusion
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Multivalent Influenza Vaccines Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Multivalent Influenza Vaccines by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Multivalent Influenza Vaccines by Country/Region, 2017, 2022 & 2028
2.2 Multivalent Influenza Vaccines Segment by Type
2.2.1 Trivalent Inactivated Influenza Vaccine (IIV3)
2.2.2 Trivalent Live Attenuated Vaccine (LAIV3)
2.2.3 Quadrivalent Inactivated Influenza Vaccine (IIV4)
2.3 Multivalent Influenza Vaccines Sales by Type
2.3.1 Global Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
2.3.2 Global Multivalent Influenza Vaccines Revenue and Market Share by Type (2017-2022)
2.3.3 Global Multivalent Influenza Vaccines Sale Price by Type (2017-2022)
2.4 Multivalent Influenza Vaccines Segment by Application
2.4.1 6 Months to 3 Years
2.4.2 Above 3 Years
2.5 Multivalent Influenza Vaccines Sales by Application
2.5.1 Global Multivalent Influenza Vaccines Sale Market Share by Application (2017-2022)
2.5.2 Global Multivalent Influenza Vaccines Revenue and Market Share by Application (2017-2022)
2.5.3 Global Multivalent Influenza Vaccines Sale Price by Application (2017-2022)
3 GLOBAL MULTIVALENT INFLUENZA VACCINES BY COMPANY
3.1 Global Multivalent Influenza Vaccines Breakdown Data by Company
3.1.1 Global Multivalent Influenza Vaccines Annual Sales by Company (2020-2022)
3.1.2 Global Multivalent Influenza Vaccines Sales Market Share by Company (2020-2022)
3.2 Global Multivalent Influenza Vaccines Annual Revenue by Company (2020-2022)
3.2.1 Global Multivalent Influenza Vaccines Revenue by Company (2020-2022)
3.2.2 Global Multivalent Influenza Vaccines Revenue Market Share by Company (2020-2022)
3.3 Global Multivalent Influenza Vaccines Sale Price by Company
3.4 Key Manufacturers Multivalent Influenza Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Multivalent Influenza Vaccines Product Location Distribution
3.4.2 Players Multivalent Influenza Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR MULTIVALENT INFLUENZA VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Multivalent Influenza Vaccines Market Size by Geographic Region (2017-2022)
4.1.1 Global Multivalent Influenza Vaccines Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Multivalent Influenza Vaccines Annual Revenue by Geographic Region
4.2 World Historic Multivalent Influenza Vaccines Market Size by Country/Region (2017-2022)
4.2.1 Global Multivalent Influenza Vaccines Annual Sales by Country/Region (2017-2022)
4.2.2 Global Multivalent Influenza Vaccines Annual Revenue by Country/Region
4.3 Americas Multivalent Influenza Vaccines Sales Growth
4.4 APAC Multivalent Influenza Vaccines Sales Growth
4.5 Europe Multivalent Influenza Vaccines Sales Growth
4.6 Middle East & Africa Multivalent Influenza Vaccines Sales Growth
5 AMERICAS
5.1 Americas Multivalent Influenza Vaccines Sales by Country
5.1.1 Americas Multivalent Influenza Vaccines Sales by Country (2017-2022)
5.1.2 Americas Multivalent Influenza Vaccines Revenue by Country (2017-2022)
5.2 Americas Multivalent Influenza Vaccines Sales by Type
5.3 Americas Multivalent Influenza Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multivalent Influenza Vaccines Sales by Region
6.1.1 APAC Multivalent Influenza Vaccines Sales by Region (2017-2022)
6.1.2 APAC Multivalent Influenza Vaccines Revenue by Region (2017-2022)
6.2 APAC Multivalent Influenza Vaccines Sales by Type
6.3 APAC Multivalent Influenza Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Multivalent Influenza Vaccines by Country
7.1.1 Europe Multivalent Influenza Vaccines Sales by Country (2017-2022)
7.1.2 Europe Multivalent Influenza Vaccines Revenue by Country (2017-2022)
7.2 Europe Multivalent Influenza Vaccines Sales by Type
7.3 Europe Multivalent Influenza Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Multivalent Influenza Vaccines by Country
8.1.1 Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2017-2022)
8.1.2 Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2017-2022)
8.2 Middle East & Africa Multivalent Influenza Vaccines Sales by Type
8.3 Middle East & Africa Multivalent Influenza Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multivalent Influenza Vaccines
10.3 Manufacturing Process Analysis of Multivalent Influenza Vaccines
10.4 Industry Chain Structure of Multivalent Influenza Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Multivalent Influenza Vaccines Distributors
11.3 Multivalent Influenza Vaccines Customer
12 WORLD FORECAST REVIEW FOR MULTIVALENT INFLUENZA VACCINES BY GEOGRAPHIC REGION
12.1 Global Multivalent Influenza Vaccines Market Size Forecast by Region
12.1.1 Global Multivalent Influenza Vaccines Forecast by Region (2023-2028)
12.1.2 Global Multivalent Influenza Vaccines Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Multivalent Influenza Vaccines Forecast by Type
12.7 Global Multivalent Influenza Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Multivalent Influenza Vaccines Product Offered
13.1.3 Sanofi Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 CSL
13.2.1 CSL Company Information
13.2.2 CSL Multivalent Influenza Vaccines Product Offered
13.2.3 CSL Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 CSL Main Business Overview
13.2.5 CSL Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Multivalent Influenza Vaccines Product Offered
13.3.3 GSK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Viatris
13.4.1 Viatris Company Information
13.4.2 Viatris Multivalent Influenza Vaccines Product Offered
13.4.3 Viatris Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Viatris Main Business Overview
13.4.5 Viatris Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca Multivalent Influenza Vaccines Product Offered
13.5.3 AstraZeneca Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Hualan Bio
13.6.1 Hualan Bio Company Information
13.6.2 Hualan Bio Multivalent Influenza Vaccines Product Offered
13.6.3 Hualan Bio Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Hualan Bio Main Business Overview
13.6.5 Hualan Bio Latest Developments
13.7 Changchun Institute of Biological
13.7.1 Changchun Institute of Biological Company Information
13.7.2 Changchun Institute of Biological Multivalent Influenza Vaccines Product Offered
13.7.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Changchun Institute of Biological Main Business Overview
13.7.5 Changchun Institute of Biological Latest Developments
13.8 Sinovac
13.8.1 Sinovac Company Information
13.8.2 Sinovac Multivalent Influenza Vaccines Product Offered
13.8.3 Sinovac Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Sinovac Main Business Overview
13.8.5 Sinovac Latest Developments
13.9 Bcht Biotechnology
13.9.1 Bcht Biotechnology Company Information
13.9.2 Bcht Biotechnology Multivalent Influenza Vaccines Product Offered
13.9.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Bcht Biotechnology Main Business Overview
13.9.5 Bcht Biotechnology Latest Developments
13.10 Jiangsu GDK
13.10.1 Jiangsu GDK Company Information
13.10.2 Jiangsu GDK Multivalent Influenza Vaccines Product Offered
13.10.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Jiangsu GDK Main Business Overview
13.10.5 Jiangsu GDK Latest Developments
13.11 KM Biologics
13.11.1 KM Biologics Company Information
13.11.2 KM Biologics Multivalent Influenza Vaccines Product Offered
13.11.3 KM Biologics Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 KM Biologics Main Business Overview
13.11.5 KM Biologics Latest Developments
13.12 ADIMMUNE Corporation
13.12.1 ADIMMUNE Corporation Company Information
13.12.2 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Offered
13.12.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 ADIMMUNE Corporation Main Business Overview
13.12.5 ADIMMUNE Corporation Latest Developments
13.13 Aleph Biomedical
13.13.1 Aleph Biomedical Company Information
13.13.2 Aleph Biomedical Multivalent Influenza Vaccines Product Offered
13.13.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Aleph Biomedical Main Business Overview
13.13.5 Aleph Biomedical Latest Developments
13.14 Shanghai Institute of Biological Products
13.14.1 Shanghai Institute of Biological Products Company Information
13.14.2 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Offered
13.14.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Shanghai Institute of Biological Products Main Business Overview
13.14.5 Shanghai Institute of Biological Products Latest Developments
13.15 Zhongyianke Biotech
13.15.1 Zhongyianke Biotech Company Information
13.15.2 Zhongyianke Biotech Multivalent Influenza Vaccines Product Offered
13.15.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Zhongyianke Biotech Main Business Overview
13.15.5 Zhongyianke Biotech Latest Developments
13.16 Wuhan Institute of Biological Products
13.16.1 Wuhan Institute of Biological Products Company Information
13.16.2 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Offered
13.16.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Wuhan Institute of Biological Products Main Business Overview
13.16.5 Wuhan Institute of Biological Products Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Multivalent Influenza Vaccines Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Multivalent Influenza Vaccines by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Multivalent Influenza Vaccines by Country/Region, 2017, 2022 & 2028
2.2 Multivalent Influenza Vaccines Segment by Type
2.2.1 Trivalent Inactivated Influenza Vaccine (IIV3)
2.2.2 Trivalent Live Attenuated Vaccine (LAIV3)
2.2.3 Quadrivalent Inactivated Influenza Vaccine (IIV4)
2.3 Multivalent Influenza Vaccines Sales by Type
2.3.1 Global Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
2.3.2 Global Multivalent Influenza Vaccines Revenue and Market Share by Type (2017-2022)
2.3.3 Global Multivalent Influenza Vaccines Sale Price by Type (2017-2022)
2.4 Multivalent Influenza Vaccines Segment by Application
2.4.1 6 Months to 3 Years
2.4.2 Above 3 Years
2.5 Multivalent Influenza Vaccines Sales by Application
2.5.1 Global Multivalent Influenza Vaccines Sale Market Share by Application (2017-2022)
2.5.2 Global Multivalent Influenza Vaccines Revenue and Market Share by Application (2017-2022)
2.5.3 Global Multivalent Influenza Vaccines Sale Price by Application (2017-2022)
3 GLOBAL MULTIVALENT INFLUENZA VACCINES BY COMPANY
3.1 Global Multivalent Influenza Vaccines Breakdown Data by Company
3.1.1 Global Multivalent Influenza Vaccines Annual Sales by Company (2020-2022)
3.1.2 Global Multivalent Influenza Vaccines Sales Market Share by Company (2020-2022)
3.2 Global Multivalent Influenza Vaccines Annual Revenue by Company (2020-2022)
3.2.1 Global Multivalent Influenza Vaccines Revenue by Company (2020-2022)
3.2.2 Global Multivalent Influenza Vaccines Revenue Market Share by Company (2020-2022)
3.3 Global Multivalent Influenza Vaccines Sale Price by Company
3.4 Key Manufacturers Multivalent Influenza Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Multivalent Influenza Vaccines Product Location Distribution
3.4.2 Players Multivalent Influenza Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR MULTIVALENT INFLUENZA VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Multivalent Influenza Vaccines Market Size by Geographic Region (2017-2022)
4.1.1 Global Multivalent Influenza Vaccines Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Multivalent Influenza Vaccines Annual Revenue by Geographic Region
4.2 World Historic Multivalent Influenza Vaccines Market Size by Country/Region (2017-2022)
4.2.1 Global Multivalent Influenza Vaccines Annual Sales by Country/Region (2017-2022)
4.2.2 Global Multivalent Influenza Vaccines Annual Revenue by Country/Region
4.3 Americas Multivalent Influenza Vaccines Sales Growth
4.4 APAC Multivalent Influenza Vaccines Sales Growth
4.5 Europe Multivalent Influenza Vaccines Sales Growth
4.6 Middle East & Africa Multivalent Influenza Vaccines Sales Growth
5 AMERICAS
5.1 Americas Multivalent Influenza Vaccines Sales by Country
5.1.1 Americas Multivalent Influenza Vaccines Sales by Country (2017-2022)
5.1.2 Americas Multivalent Influenza Vaccines Revenue by Country (2017-2022)
5.2 Americas Multivalent Influenza Vaccines Sales by Type
5.3 Americas Multivalent Influenza Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multivalent Influenza Vaccines Sales by Region
6.1.1 APAC Multivalent Influenza Vaccines Sales by Region (2017-2022)
6.1.2 APAC Multivalent Influenza Vaccines Revenue by Region (2017-2022)
6.2 APAC Multivalent Influenza Vaccines Sales by Type
6.3 APAC Multivalent Influenza Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Multivalent Influenza Vaccines by Country
7.1.1 Europe Multivalent Influenza Vaccines Sales by Country (2017-2022)
7.1.2 Europe Multivalent Influenza Vaccines Revenue by Country (2017-2022)
7.2 Europe Multivalent Influenza Vaccines Sales by Type
7.3 Europe Multivalent Influenza Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Multivalent Influenza Vaccines by Country
8.1.1 Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2017-2022)
8.1.2 Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2017-2022)
8.2 Middle East & Africa Multivalent Influenza Vaccines Sales by Type
8.3 Middle East & Africa Multivalent Influenza Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multivalent Influenza Vaccines
10.3 Manufacturing Process Analysis of Multivalent Influenza Vaccines
10.4 Industry Chain Structure of Multivalent Influenza Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Multivalent Influenza Vaccines Distributors
11.3 Multivalent Influenza Vaccines Customer
12 WORLD FORECAST REVIEW FOR MULTIVALENT INFLUENZA VACCINES BY GEOGRAPHIC REGION
12.1 Global Multivalent Influenza Vaccines Market Size Forecast by Region
12.1.1 Global Multivalent Influenza Vaccines Forecast by Region (2023-2028)
12.1.2 Global Multivalent Influenza Vaccines Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Multivalent Influenza Vaccines Forecast by Type
12.7 Global Multivalent Influenza Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Multivalent Influenza Vaccines Product Offered
13.1.3 Sanofi Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 CSL
13.2.1 CSL Company Information
13.2.2 CSL Multivalent Influenza Vaccines Product Offered
13.2.3 CSL Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 CSL Main Business Overview
13.2.5 CSL Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Multivalent Influenza Vaccines Product Offered
13.3.3 GSK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Viatris
13.4.1 Viatris Company Information
13.4.2 Viatris Multivalent Influenza Vaccines Product Offered
13.4.3 Viatris Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Viatris Main Business Overview
13.4.5 Viatris Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca Multivalent Influenza Vaccines Product Offered
13.5.3 AstraZeneca Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Hualan Bio
13.6.1 Hualan Bio Company Information
13.6.2 Hualan Bio Multivalent Influenza Vaccines Product Offered
13.6.3 Hualan Bio Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Hualan Bio Main Business Overview
13.6.5 Hualan Bio Latest Developments
13.7 Changchun Institute of Biological
13.7.1 Changchun Institute of Biological Company Information
13.7.2 Changchun Institute of Biological Multivalent Influenza Vaccines Product Offered
13.7.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Changchun Institute of Biological Main Business Overview
13.7.5 Changchun Institute of Biological Latest Developments
13.8 Sinovac
13.8.1 Sinovac Company Information
13.8.2 Sinovac Multivalent Influenza Vaccines Product Offered
13.8.3 Sinovac Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Sinovac Main Business Overview
13.8.5 Sinovac Latest Developments
13.9 Bcht Biotechnology
13.9.1 Bcht Biotechnology Company Information
13.9.2 Bcht Biotechnology Multivalent Influenza Vaccines Product Offered
13.9.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Bcht Biotechnology Main Business Overview
13.9.5 Bcht Biotechnology Latest Developments
13.10 Jiangsu GDK
13.10.1 Jiangsu GDK Company Information
13.10.2 Jiangsu GDK Multivalent Influenza Vaccines Product Offered
13.10.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Jiangsu GDK Main Business Overview
13.10.5 Jiangsu GDK Latest Developments
13.11 KM Biologics
13.11.1 KM Biologics Company Information
13.11.2 KM Biologics Multivalent Influenza Vaccines Product Offered
13.11.3 KM Biologics Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 KM Biologics Main Business Overview
13.11.5 KM Biologics Latest Developments
13.12 ADIMMUNE Corporation
13.12.1 ADIMMUNE Corporation Company Information
13.12.2 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Offered
13.12.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 ADIMMUNE Corporation Main Business Overview
13.12.5 ADIMMUNE Corporation Latest Developments
13.13 Aleph Biomedical
13.13.1 Aleph Biomedical Company Information
13.13.2 Aleph Biomedical Multivalent Influenza Vaccines Product Offered
13.13.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Aleph Biomedical Main Business Overview
13.13.5 Aleph Biomedical Latest Developments
13.14 Shanghai Institute of Biological Products
13.14.1 Shanghai Institute of Biological Products Company Information
13.14.2 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Offered
13.14.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Shanghai Institute of Biological Products Main Business Overview
13.14.5 Shanghai Institute of Biological Products Latest Developments
13.15 Zhongyianke Biotech
13.15.1 Zhongyianke Biotech Company Information
13.15.2 Zhongyianke Biotech Multivalent Influenza Vaccines Product Offered
13.15.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Zhongyianke Biotech Main Business Overview
13.15.5 Zhongyianke Biotech Latest Developments
13.16 Wuhan Institute of Biological Products
13.16.1 Wuhan Institute of Biological Products Company Information
13.16.2 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Offered
13.16.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Wuhan Institute of Biological Products Main Business Overview
13.16.5 Wuhan Institute of Biological Products Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Multivalent Influenza Vaccines Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Multivalent Influenza Vaccines Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Trivalent Inactivated Influenza Vaccine (IIV3)
Table 4. Major Players of Trivalent Live Attenuated Vaccine (LAIV3)
Table 5. Major Players of Quadrivalent Inactivated Influenza Vaccine (IIV4)
Table 6. Global Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 7. Global Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 8. Global Multivalent Influenza Vaccines Revenue by Type (2017-2022) & ($ million)
Table 9. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2017-2022)
Table 10. Global Multivalent Influenza Vaccines Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 12. Global Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 13. Global Multivalent Influenza Vaccines Revenue by Application (2017-2022)
Table 14. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2017-2022)
Table 15. Global Multivalent Influenza Vaccines Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Multivalent Influenza Vaccines Sales by Company (2020-2022) & (K Units)
Table 17. Global Multivalent Influenza Vaccines Sales Market Share by Company (2020-2022)
Table 18. Global Multivalent Influenza Vaccines Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Multivalent Influenza Vaccines Revenue Market Share by Company (2020-2022)
Table 20. Global Multivalent Influenza Vaccines Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Multivalent Influenza Vaccines Producing Area Distribution and Sales Area
Table 22. Players Multivalent Influenza Vaccines Products Offered
Table 23. Multivalent Influenza Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Multivalent Influenza Vaccines Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Multivalent Influenza Vaccines Sales Market Share Geographic Region (2017-2022)
Table 28. Global Multivalent Influenza Vaccines Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Multivalent Influenza Vaccines Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Multivalent Influenza Vaccines Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Multivalent Influenza Vaccines Sales Market Share by Country/Region (2017-2022)
Table 32. Global Multivalent Influenza Vaccines Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Multivalent Influenza Vaccines Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)
Table 35. Americas Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)
Table 36. Americas Multivalent Influenza Vaccines Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)
Table 38. Americas Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 39. Americas Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 40. Americas Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 41. Americas Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 42. APAC Multivalent Influenza Vaccines Sales by Region (2017-2022) & (K Units)
Table 43. APAC Multivalent Influenza Vaccines Sales Market Share by Region (2017-2022)
Table 44. APAC Multivalent Influenza Vaccines Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Multivalent Influenza Vaccines Revenue Market Share by Region (2017-2022)
Table 46. APAC Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 47. APAC Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 48. APAC Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 49. APAC Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 50. Europe Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)
Table 51. Europe Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)
Table 52. Europe Multivalent Influenza Vaccines Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)
Table 54. Europe Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 55. Europe Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 56. Europe Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 57. Europe Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Multivalent Influenza Vaccines
Table 67. Key Market Challenges & Risks of Multivalent Influenza Vaccines
Table 68. Key Industry Trends of Multivalent Influenza Vaccines
Table 69. Multivalent Influenza Vaccines Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Multivalent Influenza Vaccines Distributors List
Table 72. Multivalent Influenza Vaccines Customer List
Table 73. Global Multivalent Influenza Vaccines Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Multivalent Influenza Vaccines Sales Market Forecast by Region
Table 75. Global Multivalent Influenza Vaccines Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Multivalent Influenza Vaccines Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Multivalent Influenza Vaccines Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Multivalent Influenza Vaccines Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Multivalent Influenza Vaccines Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Multivalent Influenza Vaccines Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Multivalent Influenza Vaccines Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Multivalent Influenza Vaccines Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Multivalent Influenza Vaccines Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Application (2023-2028)
Table 93. Sanofi Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Sanofi Multivalent Influenza Vaccines Product Offered
Table 95. Sanofi Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Sanofi Main Business
Table 97. Sanofi Latest Developments
Table 98. CSL Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. CSL Multivalent Influenza Vaccines Product Offered
Table 100. CSL Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. CSL Main Business
Table 102. CSL Latest Developments
Table 103. GSK Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. GSK Multivalent Influenza Vaccines Product Offered
Table 105. GSK Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. GSK Main Business
Table 107. GSK Latest Developments
Table 108. Viatris Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Viatris Multivalent Influenza Vaccines Product Offered
Table 110. Viatris Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Viatris Main Business
Table 112. Viatris Latest Developments
Table 113. AstraZeneca Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. AstraZeneca Multivalent Influenza Vaccines Product Offered
Table 115. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. AstraZeneca Main Business
Table 117. AstraZeneca Latest Developments
Table 118. Hualan Bio Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Hualan Bio Multivalent Influenza Vaccines Product Offered
Table 120. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. Hualan Bio Main Business
Table 122. Hualan Bio Latest Developments
Table 123. Changchun Institute of Biological Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. Changchun Institute of Biological Multivalent Influenza Vaccines Product Offered
Table 125. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 126. Changchun Institute of Biological Main Business
Table 127. Changchun Institute of Biological Latest Developments
Table 128. Sinovac Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 129. Sinovac Multivalent Influenza Vaccines Product Offered
Table 130. Sinovac Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 131. Sinovac Main Business
Table 132. Sinovac Latest Developments
Table 133. Bcht Biotechnology Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 134. Bcht Biotechnology Multivalent Influenza Vaccines Product Offered
Table 135. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 136. Bcht Biotechnology Main Business
Table 137. Bcht Biotechnology Latest Developments
Table 138. Jiangsu GDK Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 139. Jiangsu GDK Multivalent Influenza Vaccines Product Offered
Table 140. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 141. Jiangsu GDK Main Business
Table 142. Jiangsu GDK Latest Developments
Table 143. KM Biologics Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 144. KM Biologics Multivalent Influenza Vaccines Product Offered
Table 145. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 146. KM Biologics Main Business
Table 147. KM Biologics Latest Developments
Table 148. ADIMMUNE Corporation Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 149. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Offered
Table 150. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 151. ADIMMUNE Corporation Main Business
Table 152. ADIMMUNE Corporation Latest Developments
Table 153. Aleph Biomedical Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 154. Aleph Biomedical Multivalent Influenza Vaccines Product Offered
Table 155. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 156. Aleph Biomedical Main Business
Table 157. Aleph Biomedical Latest Developments
Table 158. Shanghai Institute of Biological Products Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 159. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Offered
Table 160. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 161. Shanghai Institute of Biological Products Main Business
Table 162. Shanghai Institute of Biological Products Latest Developments
Table 163. Zhongyianke Biotech Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 164. Zhongyianke Biotech Multivalent Influenza Vaccines Product Offered
Table 165. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 166. Zhongyianke Biotech Main Business
Table 167. Zhongyianke Biotech Latest Developments
Table 168. Wuhan Institute of Biological Products Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 169. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Offered
Table 170. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 171. Wuhan Institute of Biological Products Main Business
Table 172. Wuhan Institute of Biological Products Latest Developments
Table 1. Multivalent Influenza Vaccines Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Multivalent Influenza Vaccines Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Trivalent Inactivated Influenza Vaccine (IIV3)
Table 4. Major Players of Trivalent Live Attenuated Vaccine (LAIV3)
Table 5. Major Players of Quadrivalent Inactivated Influenza Vaccine (IIV4)
Table 6. Global Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 7. Global Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 8. Global Multivalent Influenza Vaccines Revenue by Type (2017-2022) & ($ million)
Table 9. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2017-2022)
Table 10. Global Multivalent Influenza Vaccines Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 12. Global Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 13. Global Multivalent Influenza Vaccines Revenue by Application (2017-2022)
Table 14. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2017-2022)
Table 15. Global Multivalent Influenza Vaccines Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Multivalent Influenza Vaccines Sales by Company (2020-2022) & (K Units)
Table 17. Global Multivalent Influenza Vaccines Sales Market Share by Company (2020-2022)
Table 18. Global Multivalent Influenza Vaccines Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Multivalent Influenza Vaccines Revenue Market Share by Company (2020-2022)
Table 20. Global Multivalent Influenza Vaccines Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Multivalent Influenza Vaccines Producing Area Distribution and Sales Area
Table 22. Players Multivalent Influenza Vaccines Products Offered
Table 23. Multivalent Influenza Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Multivalent Influenza Vaccines Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Multivalent Influenza Vaccines Sales Market Share Geographic Region (2017-2022)
Table 28. Global Multivalent Influenza Vaccines Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Multivalent Influenza Vaccines Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Multivalent Influenza Vaccines Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Multivalent Influenza Vaccines Sales Market Share by Country/Region (2017-2022)
Table 32. Global Multivalent Influenza Vaccines Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Multivalent Influenza Vaccines Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)
Table 35. Americas Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)
Table 36. Americas Multivalent Influenza Vaccines Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)
Table 38. Americas Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 39. Americas Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 40. Americas Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 41. Americas Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 42. APAC Multivalent Influenza Vaccines Sales by Region (2017-2022) & (K Units)
Table 43. APAC Multivalent Influenza Vaccines Sales Market Share by Region (2017-2022)
Table 44. APAC Multivalent Influenza Vaccines Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Multivalent Influenza Vaccines Revenue Market Share by Region (2017-2022)
Table 46. APAC Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 47. APAC Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 48. APAC Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 49. APAC Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 50. Europe Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)
Table 51. Europe Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)
Table 52. Europe Multivalent Influenza Vaccines Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)
Table 54. Europe Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 55. Europe Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 56. Europe Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 57. Europe Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Multivalent Influenza Vaccines
Table 67. Key Market Challenges & Risks of Multivalent Influenza Vaccines
Table 68. Key Industry Trends of Multivalent Influenza Vaccines
Table 69. Multivalent Influenza Vaccines Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Multivalent Influenza Vaccines Distributors List
Table 72. Multivalent Influenza Vaccines Customer List
Table 73. Global Multivalent Influenza Vaccines Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Multivalent Influenza Vaccines Sales Market Forecast by Region
Table 75. Global Multivalent Influenza Vaccines Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Multivalent Influenza Vaccines Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Multivalent Influenza Vaccines Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Multivalent Influenza Vaccines Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Multivalent Influenza Vaccines Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Multivalent Influenza Vaccines Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Multivalent Influenza Vaccines Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Multivalent Influenza Vaccines Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Multivalent Influenza Vaccines Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Application (2023-2028)
Table 93. Sanofi Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Sanofi Multivalent Influenza Vaccines Product Offered
Table 95. Sanofi Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Sanofi Main Business
Table 97. Sanofi Latest Developments
Table 98. CSL Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. CSL Multivalent Influenza Vaccines Product Offered
Table 100. CSL Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. CSL Main Business
Table 102. CSL Latest Developments
Table 103. GSK Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. GSK Multivalent Influenza Vaccines Product Offered
Table 105. GSK Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. GSK Main Business
Table 107. GSK Latest Developments
Table 108. Viatris Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Viatris Multivalent Influenza Vaccines Product Offered
Table 110. Viatris Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Viatris Main Business
Table 112. Viatris Latest Developments
Table 113. AstraZeneca Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. AstraZeneca Multivalent Influenza Vaccines Product Offered
Table 115. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. AstraZeneca Main Business
Table 117. AstraZeneca Latest Developments
Table 118. Hualan Bio Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Hualan Bio Multivalent Influenza Vaccines Product Offered
Table 120. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. Hualan Bio Main Business
Table 122. Hualan Bio Latest Developments
Table 123. Changchun Institute of Biological Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. Changchun Institute of Biological Multivalent Influenza Vaccines Product Offered
Table 125. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 126. Changchun Institute of Biological Main Business
Table 127. Changchun Institute of Biological Latest Developments
Table 128. Sinovac Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 129. Sinovac Multivalent Influenza Vaccines Product Offered
Table 130. Sinovac Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 131. Sinovac Main Business
Table 132. Sinovac Latest Developments
Table 133. Bcht Biotechnology Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 134. Bcht Biotechnology Multivalent Influenza Vaccines Product Offered
Table 135. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 136. Bcht Biotechnology Main Business
Table 137. Bcht Biotechnology Latest Developments
Table 138. Jiangsu GDK Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 139. Jiangsu GDK Multivalent Influenza Vaccines Product Offered
Table 140. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 141. Jiangsu GDK Main Business
Table 142. Jiangsu GDK Latest Developments
Table 143. KM Biologics Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 144. KM Biologics Multivalent Influenza Vaccines Product Offered
Table 145. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 146. KM Biologics Main Business
Table 147. KM Biologics Latest Developments
Table 148. ADIMMUNE Corporation Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 149. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Offered
Table 150. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 151. ADIMMUNE Corporation Main Business
Table 152. ADIMMUNE Corporation Latest Developments
Table 153. Aleph Biomedical Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 154. Aleph Biomedical Multivalent Influenza Vaccines Product Offered
Table 155. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 156. Aleph Biomedical Main Business
Table 157. Aleph Biomedical Latest Developments
Table 158. Shanghai Institute of Biological Products Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 159. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Offered
Table 160. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 161. Shanghai Institute of Biological Products Main Business
Table 162. Shanghai Institute of Biological Products Latest Developments
Table 163. Zhongyianke Biotech Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 164. Zhongyianke Biotech Multivalent Influenza Vaccines Product Offered
Table 165. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 166. Zhongyianke Biotech Main Business
Table 167. Zhongyianke Biotech Latest Developments
Table 168. Wuhan Institute of Biological Products Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 169. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Offered
Table 170. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 171. Wuhan Institute of Biological Products Main Business
Table 172. Wuhan Institute of Biological Products Latest Developments
LIST OF FIGURES
Figure 1. Picture of Multivalent Influenza Vaccines
Figure 2. Multivalent Influenza Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Multivalent Influenza Vaccines Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Multivalent Influenza Vaccines Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Multivalent Influenza Vaccines Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Trivalent Inactivated Influenza Vaccine (IIV3)
Figure 10. Product Picture of Trivalent Live Attenuated Vaccine (LAIV3)
Figure 11. Product Picture of Quadrivalent Inactivated Influenza Vaccine (IIV4)
Figure 12. Global Multivalent Influenza Vaccines Sales Market Share by Type in 2021
Figure 13. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2017-2022)
Figure 14. Multivalent Influenza Vaccines Consumed in 6 Months to 3 Years
Figure 15. Global Multivalent Influenza Vaccines Market: 6 Months to 3 Years (2017-2022) & (K Units)
Figure 16. Multivalent Influenza Vaccines Consumed in Above 3 Years
Figure 17. Global Multivalent Influenza Vaccines Market: Above 3 Years (2017-2022) & (K Units)
Figure 18. Global Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Figure 19. Global Multivalent Influenza Vaccines Revenue Market Share by Application in 2021
Figure 20. Multivalent Influenza Vaccines Revenue Market by Company in 2021 ($ Million)
Figure 21. Global Multivalent Influenza Vaccines Revenue Market Share by Company in 2021
Figure 22. Global Multivalent Influenza Vaccines Sales Market Share by Geographic Region (2017-2022)
Figure 23. Global Multivalent Influenza Vaccines Revenue Market Share by Geographic Region in 2021
Figure 24. Global Multivalent Influenza Vaccines Sales Market Share by Region (2017-2022)
Figure 25. Global Multivalent Influenza Vaccines Revenue Market Share by Country/Region in 2021
Figure 26. Americas Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
Figure 27. Americas Multivalent Influenza Vaccines Revenue 2017-2022 ($ Millions)
Figure 28. APAC Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
Figure 29. APAC Multivalent Influenza Vaccines Revenue 2017-2022 ($ Millions)
Figure 30. Europe Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
Figure 31. Europe Multivalent Influenza Vaccines Revenue 2017-2022 ($ Millions)
Figure 32. Middle East & Africa Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
Figure 33. Middle East & Africa Multivalent Influenza Vaccines Revenue 2017-2022 ($ Millions)
Figure 34. Americas Multivalent Influenza Vaccines Sales Market Share by Country in 2021
Figure 35. Americas Multivalent Influenza Vaccines Revenue Market Share by Country in 2021
Figure 36. United States Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 37. Canada Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 38. Mexico Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 39. Brazil Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 40. APAC Multivalent Influenza Vaccines Sales Market Share by Region in 2021
Figure 41. APAC Multivalent Influenza Vaccines Revenue Market Share by Regions in 2021
Figure 42. China Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 43. Japan Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 44. South Korea Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 45. Southeast Asia Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 46. India Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 47. Australia Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 48. Europe Multivalent Influenza Vaccines Sales Market Share by Country in 2021
Figure 49. Europe Multivalent Influenza Vaccines Revenue Market Share by Country in 2021
Figure 50. Germany Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 51. France Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 52. UK Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 53. Italy Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 54. Russia Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 55. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Country in 2021
Figure 56. Middle East & Africa Multivalent Influenza Vaccines Revenue Market Share by Country in 2021
Figure 57. Egypt Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 58. South Africa Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 59. Israel Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 60. Turkey Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 61. GCC Country Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 62. Manufacturing Cost Structure Analysis of Multivalent Influenza Vaccines in 2021
Figure 63. Manufacturing Process Analysis of Multivalent Influenza Vaccines
Figure 64. Industry Chain Structure of Multivalent Influenza Vaccines
Figure 65. Channels of Distribution
Figure 66. Distributors Profiles
Figure 1. Picture of Multivalent Influenza Vaccines
Figure 2. Multivalent Influenza Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Multivalent Influenza Vaccines Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Multivalent Influenza Vaccines Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Multivalent Influenza Vaccines Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Trivalent Inactivated Influenza Vaccine (IIV3)
Figure 10. Product Picture of Trivalent Live Attenuated Vaccine (LAIV3)
Figure 11. Product Picture of Quadrivalent Inactivated Influenza Vaccine (IIV4)
Figure 12. Global Multivalent Influenza Vaccines Sales Market Share by Type in 2021
Figure 13. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2017-2022)
Figure 14. Multivalent Influenza Vaccines Consumed in 6 Months to 3 Years
Figure 15. Global Multivalent Influenza Vaccines Market: 6 Months to 3 Years (2017-2022) & (K Units)
Figure 16. Multivalent Influenza Vaccines Consumed in Above 3 Years
Figure 17. Global Multivalent Influenza Vaccines Market: Above 3 Years (2017-2022) & (K Units)
Figure 18. Global Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
Figure 19. Global Multivalent Influenza Vaccines Revenue Market Share by Application in 2021
Figure 20. Multivalent Influenza Vaccines Revenue Market by Company in 2021 ($ Million)
Figure 21. Global Multivalent Influenza Vaccines Revenue Market Share by Company in 2021
Figure 22. Global Multivalent Influenza Vaccines Sales Market Share by Geographic Region (2017-2022)
Figure 23. Global Multivalent Influenza Vaccines Revenue Market Share by Geographic Region in 2021
Figure 24. Global Multivalent Influenza Vaccines Sales Market Share by Region (2017-2022)
Figure 25. Global Multivalent Influenza Vaccines Revenue Market Share by Country/Region in 2021
Figure 26. Americas Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
Figure 27. Americas Multivalent Influenza Vaccines Revenue 2017-2022 ($ Millions)
Figure 28. APAC Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
Figure 29. APAC Multivalent Influenza Vaccines Revenue 2017-2022 ($ Millions)
Figure 30. Europe Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
Figure 31. Europe Multivalent Influenza Vaccines Revenue 2017-2022 ($ Millions)
Figure 32. Middle East & Africa Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
Figure 33. Middle East & Africa Multivalent Influenza Vaccines Revenue 2017-2022 ($ Millions)
Figure 34. Americas Multivalent Influenza Vaccines Sales Market Share by Country in 2021
Figure 35. Americas Multivalent Influenza Vaccines Revenue Market Share by Country in 2021
Figure 36. United States Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 37. Canada Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 38. Mexico Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 39. Brazil Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 40. APAC Multivalent Influenza Vaccines Sales Market Share by Region in 2021
Figure 41. APAC Multivalent Influenza Vaccines Revenue Market Share by Regions in 2021
Figure 42. China Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 43. Japan Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 44. South Korea Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 45. Southeast Asia Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 46. India Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 47. Australia Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 48. Europe Multivalent Influenza Vaccines Sales Market Share by Country in 2021
Figure 49. Europe Multivalent Influenza Vaccines Revenue Market Share by Country in 2021
Figure 50. Germany Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 51. France Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 52. UK Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 53. Italy Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 54. Russia Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 55. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Country in 2021
Figure 56. Middle East & Africa Multivalent Influenza Vaccines Revenue Market Share by Country in 2021
Figure 57. Egypt Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 58. South Africa Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 59. Israel Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 60. Turkey Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 61. GCC Country Multivalent Influenza Vaccines Revenue Growth 2017-2022 ($ Millions)
Figure 62. Manufacturing Cost Structure Analysis of Multivalent Influenza Vaccines in 2021
Figure 63. Manufacturing Process Analysis of Multivalent Influenza Vaccines
Figure 64. Industry Chain Structure of Multivalent Influenza Vaccines
Figure 65. Channels of Distribution
Figure 66. Distributors Profiles
